{"transactions":[{"id":1861743,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T22:13:38.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":9.01,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-035562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919123035562/doc4.xml","form_type":"4"}},{"id":1876602,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T21:39:00.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2024 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":30000,"derivative":{"exercise_price":2.26,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-032659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123032659/doc4.xml","form_type":"4"}},{"id":1891579,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (Right to Buy)","published_at":"2023-05-16T20:08:52.000Z","date":"2023-02-16","kind":"purchase","planned":false,"acquired":true,"shares":472800,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The warrant was purchased in the Issuer's private offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":472800,"derivative":{"exercise_price":3.96,"exercise_date":"2023-02-16","expiration_date":"2028-02-16","underlying":"Common Stock","underlying_shares":472800},"source":{"system":"sec-edgar","filing":"0001209191-23-029764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123029764/doc4.xml","form_type":"4"}},{"id":1891578,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-16T20:08:52.000Z","date":"2023-02-16","kind":"purchase","planned":false,"acquired":true,"shares":630400,"price":3.17,"value":1998368.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in the Issuer's private offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the combined purchase price of $3.17 for Common Stock and Warrants acquired from Issuer in a private offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1326305,"source":{"system":"sec-edgar","filing":"0001209191-23-029764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919123029764/doc4.xml","form_type":"4"}},{"id":1897814,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T21:47:37.000Z","date":"2023-05-08","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":8,"value":1000000.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were purchased in the Issuer's public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":2188713,"source":{"system":"sec-edgar","filing":"0001209191-23-028533","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919123028533/doc4.xml","form_type":"4"}},{"id":2116265,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T01:02:54.000Z","date":"2022-11-15","kind":"sale","acquired":false,"shares":93770,"price":19.6867,"value":1846021.859,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $20.32, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1621118,"source":{"system":"sec-edgar","filing":"0000899243-22-035944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000089924322035944/doc4.xml","form_type":"4"}},{"id":2116264,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T01:02:54.000Z","date":"2022-11-14","kind":"sale","acquired":false,"shares":32109,"price":19.6027,"value":629423.0943,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.105 to $20.43, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1714888,"source":{"system":"sec-edgar","filing":"0000899243-22-035944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000089924322035944/doc4.xml","form_type":"4"}},{"id":2116263,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-16T01:02:54.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":174121,"price":19.9942,"value":3481410.0982,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.28, inclusive. The reporting persons undertake to provide Mirum Pharmaceuticals, Inc., any security holder of Mirum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1746997,"source":{"system":"sec-edgar","filing":"0000899243-22-035944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000089924322035944/doc4.xml","form_type":"4"}},{"id":2242489,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T21:55:09.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2023 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":23.51,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-22-034628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919122034628/doc4.xml","form_type":"4"}},{"id":2243818,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-03T21:00:36.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 1, 2023 or the day prior to the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":17500,"derivative":{"exercise_price":2.09,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-034175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919122034175/doc4.xml","form_type":"4"}},{"id":2253529,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T20:16:23.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2023 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":22500,"derivative":{"exercise_price":1.32,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-032519","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919122032519/doc4.xml","form_type":"4"}},{"id":2677794,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-08T20:38:13.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Company's 2022 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":16.88,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-21-038932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919121038932/doc4.xml","form_type":"4"}},{"id":2700951,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-22T01:09:59.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2022 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":10000,"derivative":{"exercise_price":15.24,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-035150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919121035150/doc4.xml","form_type":"4"}},{"id":2748261,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-15T20:16:55.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":3710116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":829113},"source":{"system":"sec-edgar","filing":"0001209191-21-026826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026826/doc4.xml","form_type":"4"}},{"id":2748260,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-15T20:16:55.000Z","date":"2021-04-13","kind":"exercise","acquired":false,"shares":4629630,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1034600},"source":{"system":"sec-edgar","filing":"0001209191-21-026826","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026826/doc4.xml","form_type":"4"}},{"id":2748259,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T20:16:55.000Z","date":"2021-04-13","kind":"purchase","acquired":true,"shares":200000,"price":15,"value":3000000.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":2063713,"source":{"system":"sec-edgar","filing":"0001209191-21-026826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026826/doc4.xml","form_type":"4"}},{"id":2748258,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T20:16:55.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":829113,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":1863713,"source":{"system":"sec-edgar","filing":"0001209191-21-026826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026826/doc4.xml","form_type":"4"}},{"id":2748257,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-15T20:16:55.000Z","date":"2021-04-13","kind":"exercise","acquired":true,"shares":1034600,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 4.4748 shares of Preferred Stock. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by RiverVest Venture Fund IV, L.P. (\"RiverVest Fund IV\")  are indirectly held by RiverVest Venture Partners IV, L.P., its general partner (\"RiverVest Partners IV\"). RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV. The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and the Reporting Person. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers (including the Reporting Person) share voting and dispositive power with regard to the Company's securities directly held by RiverVest Fund IV."}],"balance_after":1034600,"source":{"system":"sec-edgar","filing":"0001209191-21-026826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026826/doc4.xml","form_type":"4"}},{"id":2751068,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-12T19:18:15.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on April 8, 2022."}],"balance_after":14000,"derivative":{"exercise_price":15,"expiration_date":"2031-04-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-21-026340","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1637715/000120919121026340/doc4.xml","form_type":"4"}},{"id":3005322,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-16T16:21:06.000Z","date":"2020-10-14","kind":"exercise","acquired":false,"shares":2916664,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":445905},"source":{"system":"sec-edgar","filing":"0001209191-20-055015","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055015/doc4.xml","form_type":"4"}},{"id":3005321,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:21:06.000Z","date":"2020-10-14","kind":"purchase","acquired":true,"shares":250000,"price":15,"value":3750000.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":695905,"source":{"system":"sec-edgar","filing":"0001209191-20-055015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055015/doc4.xml","form_type":"4"}},{"id":3005320,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-10-16T16:21:06.000Z","date":"2020-10-14","kind":"exercise","acquired":true,"shares":445905,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 0.152881822351322 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering on October 14, 2020 (on an adjusted basis, after giving effect to the 1-for-6.541 reverse stock split of the common stock effected by the Issuer on October 2, 2020). The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P. The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":445905,"source":{"system":"sec-edgar","filing":"0001209191-20-055015","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000120919120055015/doc4.xml","form_type":"4"}},{"id":3110715,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-15T20:20:56.000Z","date":"2020-06-11","kind":"grant","acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2021 annual stockholder meeting."}],"balance_after":17000,"derivative":{"exercise_price":16.71,"expiration_date":"2030-06-10","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001209191-20-036597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919120036597/doc4.xml","form_type":"4"}},{"id":3456809,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-07-24T20:16:11.000Z","date":"2019-07-22","kind":"exercise","acquired":false,"shares":11968944,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P.  The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1496118},"source":{"system":"sec-edgar","filing":"0001209191-19-043023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119043023/doc4.xml","form_type":"4"}},{"id":3456808,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-24T20:16:11.000Z","date":"2019-07-22","kind":"purchase","acquired":true,"shares":300000,"price":15,"value":4500000.0,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P.  The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1921118,"source":{"system":"sec-edgar","filing":"0001209191-19-043023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119043023/doc4.xml","form_type":"4"}},{"id":3456807,"issuer":{"id":2416,"kind":"organization","name":"Mirum Pharmaceuticals, Inc.","symbol":"MIRM"},"owners":[{"id":112553,"kind":"person","name":"O'Donnell Niall","position":1,"cik":"0001780235","reported_name":"O'Donnell Niall","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-24T20:16:11.000Z","date":"2019-07-22","kind":"exercise","acquired":true,"shares":1496118,"ownership":{"direct":false,"nature":"By RiverVest Venture Fund IV, L.P."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Automatic conversion, in connection with the Issuer's initial public offering, of each share of the Issuer's Series A preferred stock into 0.125 shares of the Issuer's common stock. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RiverVest Venture Partners IV, L.P. is the general partner of RiverVest Venture Fund IV, L.P. The Reporting Person is a manager of RiverVest Venture Partners IV, LLC, the sole general partner of RiverVest Venture Partners IV, L.P., and as a result may be deemed to share dispositive voting and investment power with respect to the shares held by RiverVest Venture Partners IV, L.P.  The Reporting Person disclaims beneficial ownership of all shares held by RiverVest Venture Partners IV, L.P. except to the extent of his pecuniary interests therein."}],"balance_after":1621118,"source":{"system":"sec-edgar","filing":"0001209191-19-043023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1759425/000120919119043023/doc4.xml","form_type":"4"}}]}